The consensus analyst price target for Alkermes stock was recently lowered from $44 to $43.88, following several updates to the company’s outlook. This minor adjustment reflects a combination of ...
Lundbeck had tried to scoop the narcolepsy drug maker out from under Alkeremes with $2.4 billion, but Avadel has elected to ...
Facing the fact that Lundbeck’s unexpected offer for Avadel Pharmaceuticals was sweeter, Alkermes has come back to the ...
In a statement, Denmark-based Lundbeck said it had carried out a "comprehensive assessment" of the bids on the table for ...
Further to the announcement under Rule 2.7 of the Irish Takeover Rules by Avadel and Alkermes on November 19, 2025, Danish ...
Shortly after Alkermes and Avadel announced their deal, Lundbeck made an unsolicited offer of $23 per share, including $21 ...
Investor's Business Daily on MSN
Alkermes Ups Its Avadel Bid To $2.37 Billion In A Buyout Battle With Lundbeck
Alkermes upped its bid on Avadel to $2.37 billion on Wednesday, coming in with the "superior proposal" vs. Lundbeck's ...
Avadel Pharmaceuticals said on Wednesday its board has determined that a sweetened offer from Alkermes was superior to a ...
Alixorexton’s Phase II performance sets it up for late-stage success, according to analysts at Truist Securities. Alkermes expects to launch a global late-stage program early next year for narcolepsy ...
Alkermes plc (Nasdaq: ALKS) ("Alkermes") and Avadel Pharmaceuticals plc (Nasdaq: AVDL) ("Avadel") today announced that the companies have reached agreement on the terms of an increased recommended ...
Alkermes said on Friday it is reviewing its options after Avadel Pharmaceuticals received an unsolicited takeover proposal from Danish drugmaker Lundbeck that tops Alkermes' agreed-upon deal. Shares ...
Detailed price information for Avadel Pharmaceuticals Plc ADR (AVDL-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback